初发T2DM患者随机分为甘精胰岛素联合阿卡波糖组(A组)和预混胰岛素组(B组),每组各20例,共治疗12周。结果:空腹血糖(FBG),糖化血红蛋白(HbA1c)在4周和12周末均明显下降(P<0.01),且A组大于B组,A组低血糖发生率明显低于B组(P<0.05)。结论:对于初发T2DM患者每日一次甘精胰岛素联合阿卡波糖或每日两次预混胰岛素治疗均能达到明显的降糖效果,改善胰岛功能。前者降低FBG的效果更好,且低血糖发生率更低。 Patients with newly diagnosed T2DM were randomized into insulin glargine combined with acarbose group (Group A) and premixed insulin group (Group B), 20 patients in each group for 12 weeks. Results: Fasting plasma glucose (FBG) and HbA1c were significantly decreased at 4 and 12 weeks (P <0.01), and group A was greater than group B. The incidence of hypoglycemia in group A was significantly lower than that in group B (P <0.05) ). CONCLUSIONS: Glargine and Acarbose once daily or premixed insulin twice a day for early-onset T2DM patients achieve significant hypoglycemic effect and improve islet function. The former is more effective in reducing FBG, and the incidence of hypoglycemia is lower.